Research programme: pain therapy - Grunenthal/Lundbeck
Latest Information Update: 25 Jul 2007
At a glance
- Originator Grunenthal; Lundbeck Research USA
- Developer Lundbeck Research USA
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 18 Mar 2003 Synaptic Pharmaceutical has been acquired by Lundbeck A/S
- 04 Dec 2000 Preclinical development for Pain in USA (Unknown route)